Exchange: NYSE·Updated 03:30 PM EDT
News
all
press releases
Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus
NKTR's Q2 earnings beat estimates, but revenues fall short. Investor focus stays on rezpeg as late-stage studies advance in autoimmune diseases.
Zacks
More News
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger
Key PointsIts drug, Foundayo, will compete in Britain against Novo Nordisk's Wegovy...
Nasdaq News: Markets
3 Large-Cap Stocks to Watch as Pharma Recovery Takes Hold
In the Large-Cap Pharmaceuticals industry, LLY, J&J and BAYRY are worth watching as the industry shows a strong recovery.
Zacks
Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity
Key PointsEli Lilly has faced spotty insurance coverage for its GLP-1 medicines in the weight-loss market...
Nasdaq News: Markets
Should Investors Buy WST as HVP Growth Meets a Premium Valuation?
WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.
Zacks
WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story
West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.
Zacks
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?
NVO's GLP-1 pills offer fresh momentum, but Eli Lilly's fast-growing injectable and oral therapies threaten to widen the competitive gap.
Zacks
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?
Lilly's Foundayo records $98M in Q2 sales, while rising prescriptions, broader access and global expansion set the stage for H2 growth
Zacks
Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'
Novo Nordisk CEO defended the company's decision to sue rival Eli Lilly over its weight-loss drug advertising...
CNBC: Mad Money with Jim Cramer
Eli Lilly Sues Six Companies Over Unauthorized Retatrutide Sales
(RTTNews) - Eli Lilly (LLY) on Wednesday filed six lawsuits against U.S. companies it accused of illegally selling unauthorized versions of its experimental obesity drug retatrutide, escalating its efforts to crack down on black-market products before the medicine receives regula...
Nasdaq News: Markets

Advertisement|Remove ads.